229 related articles for article (PubMed ID: 22962530)
21. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture.
Zhou W; Schaack J; Zawada WM; Freed CR
Brain Res; 2002 Feb; 926(1-2):42-50. PubMed ID: 11814405
[TBL] [Abstract][Full Text] [Related]
23. Genetic inactivation of alpha-synuclein affects embryonic development of dopaminergic neurons of the substantia nigra, but not the ventral tegmental area, in mouse brain.
Tarasova TV; Lytkina OA; Goloborshcheva VV; Skuratovskaya LN; Antohin AI; Ovchinnikov RK; Kukharsky MS
PeerJ; 2018; 6():e4779. PubMed ID: 29785351
[TBL] [Abstract][Full Text] [Related]
24. Membrane insertion exacerbates the α-Synuclein-Cu(II) dopamine oxidase activity: Metallothionein-3 targets and silences all α-synuclein-Cu(II) complexes.
Calvo JS; Mulpuri NV; Dao A; Qazi NK; Meloni G
Free Radic Biol Med; 2020 Oct; 158():149-161. PubMed ID: 32712192
[TBL] [Abstract][Full Text] [Related]
25. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
[TBL] [Abstract][Full Text] [Related]
26. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells.
Yamakawa K; Izumi Y; Takeuchi H; Yamamoto N; Kume T; Akaike A; Takahashi R; Shimohama S; Sawada H
Biochem Biophys Res Commun; 2010 Jan; 391(1):129-34. PubMed ID: 19900407
[TBL] [Abstract][Full Text] [Related]
27. Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures.
Park SS; Lee D
Eur J Neurosci; 2006 Jun; 23(11):2908-14. PubMed ID: 16819979
[TBL] [Abstract][Full Text] [Related]
28. Identification of an Alternatively Spliced α-Synuclein Isoform That Generates a 41-Amino Acid N-Terminal Truncated Peptide, 41-syn: Role in Dopamine Homeostasis.
Vinnakota RL; Yedlapudi D; Manda KM; Bhamidipati K; Bommakanti KT; RangaLakshmi GS; Kalivendi SV
ACS Chem Neurosci; 2018 Dec; 9(12):2948-2958. PubMed ID: 29996045
[TBL] [Abstract][Full Text] [Related]
29. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
[TBL] [Abstract][Full Text] [Related]
30. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
31. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
Xu S; Chan P
Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
[TBL] [Abstract][Full Text] [Related]
32. Dopamine and Cu+/2+ can induce oligomerization of α-synuclein in the absence of oxygen: Two types of oligomerization mechanisms for α-synuclein and related cell toxicity studies.
Ha Y; Yang A; Lee S; Kim K; Liew H; Lee SH; Lee JE; Lee HI; Suh YH; Park HS; Churchill DG
J Neurosci Res; 2014 Mar; 92(3):359-68. PubMed ID: 24288134
[TBL] [Abstract][Full Text] [Related]
33. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
Park SS; Schulz EM; Lee D
Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
[TBL] [Abstract][Full Text] [Related]
34. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
[TBL] [Abstract][Full Text] [Related]
35. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.
Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R
J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
37. Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate.
Faustini G; Longhena F; Bruno A; Bono F; Grigoletto J; La Via L; Barbon A; Casiraghi A; Straniero V; Valoti E; Costantino G; Benfenati F; Missale C; Pizzi M; Spillantini MG; Bellucci A
Neurobiol Dis; 2020 May; 138():104789. PubMed ID: 32032728
[TBL] [Abstract][Full Text] [Related]
38. Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers.
Lee HJ; Baek SM; Ho DH; Suk JE; Cho ED; Lee SJ
Exp Mol Med; 2011 Apr; 43(4):216-22. PubMed ID: 21415592
[TBL] [Abstract][Full Text] [Related]
39. Application of a C. elegans dopamine neuron degeneration assay for the validation of potential Parkinson's disease genes.
Berkowitz LA; Hamamichi S; Knight AL; Harrington AJ; Caldwell GA; Caldwell KA
J Vis Exp; 2008 Jul; (17):. PubMed ID: 19066512
[TBL] [Abstract][Full Text] [Related]
40. Glutathione
Jewett M; Dickson E; Brolin K; Negrini M; Jimenez-Ferrer I; Swanberg M
Front Neurol; 2018; 9():222. PubMed ID: 29681884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
